Måndag 2 Juni | 21:27:32 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-11-21 08:00 Kvartalsrapport 2025-Q3
2025-08-29 08:00 Kvartalsrapport 2025-Q2
2025-05-28 - Kvartalsrapport 2025-Q1
2025-05-19 - X-dag ordinarie utdelning ISAB 0.00 SEK
2025-05-16 - Årsstämma
2025-05-08 - Extra Bolagsstämma 2025
2025-02-28 - Bokslutskommuniké 2024
2024-11-20 - Kvartalsrapport 2024-Q3
2024-09-04 - Extra Bolagsstämma 2024
2024-08-28 - Kvartalsrapport 2024-Q2
2024-05-28 - Kvartalsrapport 2024-Q1
2024-05-15 - X-dag ordinarie utdelning ISAB 0.00 SEK
2024-05-14 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-22 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-31 - Kvartalsrapport 2023-Q1
2023-05-15 - X-dag ordinarie utdelning ISAB 0.00 SEK
2023-05-12 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-06-08 - X-dag ordinarie utdelning ISAB 0.00 SEK
2022-05-23 - Kvartalsrapport 2022-Q1
2022-05-06 - Årsstämma
2022-02-28 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-06-22 - Extra Bolagsstämma 2021
2021-06-09 - X-dag ordinarie utdelning ISAB 0.00 SEK
2021-06-08 - Årsstämma
2021-05-19 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-26 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-06-12 - Extra Bolagsstämma 2020
2020-05-13 - X-dag ordinarie utdelning ISAB 0.00 SEK
2020-05-12 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-22 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-05-10 - X-dag ordinarie utdelning ISAB 0.00 SEK
2019-02-21 - Bokslutskommuniké 2018
2018-12-13 - Extra Bolagsstämma 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-05-24 - X-dag ordinarie utdelning ISAB 0.00 SEK
2018-05-23 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-11-17 - Kvartalsrapport 2017-Q3
2017-08-28 - Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Inhalation Sciences Sweden, ISAB, är ett forskningsbolag. Idag innehas störst fokus mot framställning och utvecklande av laboratorieinstrument. Instrumenten används för att mäta partiklar i inandningsluften och hur luftens sammansättning påverkar lungorna. Bolaget säljer produkter under varierade varumärken, främst på den europeiska marknaden. Inhalation Sciences Sweden grundades 2004 och har sitt huvudkontor i Huddinge.
2025-05-27 08:00:00

Stockholm, May 27, 2025 - Inhalation Sciences Sweden AB (ISAB) has recruited Ulf Wedenberg as its new Chief Commercial Officer (CCO). The recruitment comes at a crucial time for the company, where international interest in ISAB's unique inhalation technologies and CRO services has increased significantly - especially after the recently presented FDA study that further confirmed the company's scientific and regulatory relevance.

Ulf Wedenberg has over 25 years of experience from leading roles in sales, marketing and business development in the pharmaceutical and medical device sector. He has previously held key positions in companies such as Mölnlycke Healthcare, Nycomed och SHL Healthcare, where he built and led international commercial organizations with a focus on profitable growth and long-term market establishment.

"Inhalation Sciences has world-leading, patented technologies and offers unique CRO services in inhaled and nasally administered drugs. The company is in a very dynamic phase with a strong focus on growth. I am proud to become part of the team and look forward to contributing to the company's development together with all the dedicated colleagues", says Ulf Wedenberg.

"We are very pleased to welcome Ulf to ISAB. This appointment is in line with our strategy to drive continued growth and strengthen our market position. With Ulf's experience and commercial expertise, we are gaining an important reinforcement in our commercial efforts", says Manoush Masarrat, CEO of Inhalation Sciences.

Ulf Wedenberg will assume his new role on June 2, 2025.

For more information, please contact:

Manoush Masarrat, CEO

E-mail: manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

 

About Inhalation Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.